CORRESP Filing
Liminatus Pharma, Inc.
Date: Aug. 11, 2025 · CIK: 0001971387 · Accession: 0001104659-25-076067
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288289
Letter
Liminatus Pharma, Inc.
6 Centerpointe Drive #625
La Palma, CA 90623
VIA EDGAR
August 11, 2025
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
Tim Buchmiller
Re: Liminatus Pharma, Inc.
Registration Statement on Form S-1
File No. 333-288289
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Liminatus Pharma, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on August 12, 2025, or as soon as thereafter practicable.
Very truly yours,
/s/ Chris Kim
Show Raw Text
CORRESP 1 filename1.htm Liminatus Pharma, Inc. 6 Centerpointe Drive #625 La Palma, CA 90623 VIA EDGAR August 11, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Tim Buchmiller Re: Liminatus Pharma, Inc. Registration Statement on Form S-1 File No. 333-288289 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Liminatus Pharma, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on August 12, 2025, or as soon as thereafter practicable. Very truly yours, /s/ Chris Kim Chris Kim, Chief Executive Officer